MARKET

NVRO

NVRO

Nevro Corp
NYSE
9.46
+0.29
+3.16%
Opening 13:22 07/15 EDT
OPEN
9.18
PREV CLOSE
9.17
HIGH
9.46
LOW
9.08
VOLUME
160.56K
TURNOVER
0
52 WEEK HIGH
25.71
52 WEEK LOW
7.46
MARKET CAP
347.45M
P/E (TTM)
-4.1449
1D
5D
1M
3M
1Y
5Y
1D
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. Granted inducement restricted stock unit awards covering 69,201 shares of Nevro's common stock to 17 new non-executive employees on July 7, 2024. Nevro is a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. The company's 10 kHz Therapy has impacted the lives of more than 115,000 patients globally.
PR Newswire · 3d ago
Here's Why You Should Retain Nevro (NVRO) Stock for Now
NASDAQ · 3d ago
Nevro Up Nearly 15%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk
Dow Jones · 4d ago
Nevro Is Maintained at Sell by Citigroup
Dow Jones · 4d ago
Citigroup Maintains Sell on Nevro, Lowers Price Target to $8.2
Benzinga · 4d ago
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024
Nevro Corp. Will release its financial results for the second quarter of 2024 after the market closes on August 6, 2024. The company will also host a conference call to discuss the financial results. Nevro is a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain.
PR Newswire · 5d ago
Weekly Report: what happened at NVRO last week (0701-0705)?
Weekly Report · 07/08 09:23
Weekly Report: what happened at NVRO last week (0624-0628)?
Weekly Report · 07/01 09:23
More
About NVRO
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Webull offers Nevro Corp stock information, including NYSE: NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.